Related Experiment Video
Updated: Jan 30, 2026

Focus Formation: A Cell-based Assay to Determine the Oncogenic Potential of a Gene
Published on: December 31, 2014
DGKZ Acts as a Potential Oncogene in Osteosarcoma Proliferation Through Its Possible Interaction With ERK1/2 and MYC
Wenxi Yu1, Lina Tang1, Feng Lin1
1Department of Oncology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China.
Abstract:
Osteosarcoma (OS) is one of the most common primary bone tumors in children and young adults. The majority of osteosarcoma patients have limited alternative therapeutic options and metastatic patients generally have a poor prognosis. Thus, it is important to explore novel effective therapeutic targets in the treatment of osteosarcoma. Diacylglycerol kinase zeta (DGKZ) is a recently identified gene potentially associated with certain human carcinogenesis. However, the role of DGKZ in proliferation of osteosarcoma is still unclear. In this study, DGKZ's expression was firstly investigated in OS tumor samples and correlated with poor outcome in OS patients. Silence of DGKZ by shRNA hampered osteosarcoma cell growth and promoted cell apoptosis in vitro. In vivo, DGKZ's knockout also suppressed xenograft tumor proliferation as determined by bioluminescence imaging and weight/volume measurements. Meanwhile, Affymetrix GeneChip and Ingenuity Pathway Analysis (IPA) revealed that DGKZ knockdown resulted in a decreased activity of MYC pathway, and several target genes expression in MYC pathway were altered, including CCND1, CDKN2B, CDK6, PCNA, and EGR1. Furthermore, immunoprecipitation coupled with mass spectrometry (IP-MS) analysis was used to identify proteins that interacted with DGKZ in OS cells and revealed ERK1/2, a key MYC-interactor, to associate with DGKZ. Together, our study demonstrated that DGKZ might act as an oncogene in osteosarcoma via its possible interaction with ERK1/2 and MYC pathway.
Insights
Diacylglycerol kinase zeta (DGKZ) acts as an oncogene in osteosarcoma, promoting tumor growth. Silencing DGKZ inhibits osteosarcoma cell proliferation and tumor growth by affecting the MYC pathway.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Osteosarcoma (OS) is a primary bone cancer with limited treatment options, especially for metastatic cases.
- Identifying novel therapeutic targets is crucial for improving osteosarcoma patient outcomes.
- The role of Diacylglycerol kinase zeta (DGKZ) in osteosarcoma proliferation remains largely unknown.
Purpose of the Study:
- To investigate the role of DGKZ in osteosarcoma.
- To determine if DGKZ expression correlates with patient prognosis.
- To elucidate the molecular mechanisms by which DGKZ influences osteosarcoma growth.
Main Methods:
- DGKZ expression analysis in OS tumor samples.
- In vitro studies using shRNA to silence DGKZ in osteosarcoma cells.
- In vivo xenograft studies with DGKZ knockout.
- Gene expression profiling using Affymetrix GeneChip and Ingenuity Pathway Analysis (IPA).
- Protein-protein interaction studies using immunoprecipitation coupled with mass spectrometry (IP-MS).
Main Results:
- DGKZ expression was elevated in OS tumors and associated with poor prognosis.
- DGKZ silencing inhibited osteosarcoma cell growth and induced apoptosis in vitro.
- DGKZ knockout suppressed tumor growth in vivo.
- DGKZ knockdown led to decreased MYC pathway activity, altering target genes like CCND1, CDKN2B, CDK6, PCNA, and EGR1.
- DGKZ was found to interact with ERK1/2, a known MYC pathway component.
Conclusions:
- DGKZ functions as an oncogene in osteosarcoma.
- DGKZ promotes osteosarcoma proliferation, potentially through interaction with ERK1/2 and modulation of the MYC pathway.
- DGKZ represents a potential therapeutic target for osteosarcoma treatment.
Related Concept Videos
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Forces Acting on Chromosomes
Microtubules and motor proteins exert two types of forces on...
Abnormal Proliferation
Predator-Prey Interactions

